Table 2.

Mean pharmacokinetic parameter estimates for abacavir following oral administration of single 100- to 1,200-mg doses to HIV-infected adults under fasting conditionsa

Dose (mg)AUC0–∞ (μg · h/ml)Cmax (μg/ml)Tmax (h)t1/2β (h)CL/ F (ml/min/kg)
1000.99 (66)0.58 (59)1.15 (46)0.87 (20)32.4 (57)
3006.00 (46)2.87 (44)1.03 (28)1.18 (14)13.4 (41)
300 (solution)6.02 (49)2.83 (31)0.66 (44)1.52 (33)13.0 (38)
60015.7 (48)4.73 (31)1.71 (44)1.74 (31)10.2 (41)
90025.0 (47)8.10 (32)1.60 (33)1.74 (31)9.4 (34)
1,20032.8 (42)9.62 (33)1.56 (27)1.67 (14)9.3 (30)
  • a n = 11 for the 100-mg dose; n = 9 for the 300-mg dose as a caplet; n = 6 for the 300-mg dose in solution; n = 8 for all other doses. Values in parentheses are coefficients of variation.